H1-10

Histone H1.10 · Q92522 · H1-10 on Sugi Atlas →

0 patent compounds predicted against H1-10, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to H1-10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure PHASE3ACTIVE_NOT_RECRUITING
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors PHASE2RECRUITING
Descartes-08 for Patients With Systemic Lupus Erythematosus PHASE2ACTIVE_NOT_RECRUITING
Vorinostat in Children PHASE1/PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease PHASE2COMPLETED
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors PHASE2RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1COMPLETED
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes PHASE1COMPLETED
Intravenously Administered M6229 in Critically Ill Sepsis Patients PHASE1COMPLETED
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors PHASE1UNKNOWN
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma PHASE1RECRUITING
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors PHASE1RECRUITING
Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer PHASE1RECRUITING
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells PHASE1RECRUITING
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins nanCOMPLETED
MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a H1-10 binder may also engage these)

ProteinNameSimilarity
P06348 0.987 P06348 →
Q07133 0.986 Q07133 →
P06349 0.984 P06349 →
P40286 0.981 P40286 →
P22492 0.981 P22492 →
Q6P747 0.979 Q6P747 →
Q08DU9 0.979 Q08DU9 →
P15308 0.979 P15308 →
Q94AD1 0.979 Q94AD1 →
Q9VLK2 0.979 Q9VLK2 →
Q5SSJ5 0.978 Q5SSJ5 →
Q3TEA8 0.978 Q3TEA8 →
Q18336 0.977 Q18336 →
Q5ZM33 0.976 Q5ZM33 →
Q9U761 0.976 Q9U761 →
Q5UPU2 0.976 Q5UPU2 →
Q75C22 0.975 Q75C22 →
Q24595 0.974 Q24595 →
Q9M5W4 0.973 Q9M5W4 →
A2Y7R3 0.973 A2Y7R3 →
P29548 0.973 P29548 →
P29172 0.973 P29172 →
Q196Z0 0.973 Q196Z0 →
Q9U762 0.973 Q9U762 →
P50565 0.973 P50565 →
Q43261 0.973 Q43261 →
A2WKS8 0.972 A2WKS8 →
A2WKS3 0.972 A2WKS3 →
Q29187 0.972 Q29187 →
P16458 0.972 P16458 →